Abiopharma

BrightSpire Capital Announces $0.16 Per Share Dividend for Second Quarter 2026

Bryn Mawr Trust Advisors Elevates Leadership for Client Growth

Obagi Medical Announces FDA Approval of Obagi® saypha® ChIQ™ Injectable Hyaluronic Acid Gel

XBiotech startet klinische Phase-II-Studie zur Bewertung von Vilamakitug bei der Behandlung der aktiven axialen Spondyloarthritis

XBiotech lance un essai clinique de phase II visant à évaluer le vilamakitug dans le traitement de la spondylarthrite axiale active

Meet the New Chase Sapphire Preferred: Earn More Than Ever, Same $95 Annual Fee

Celanese and Siegwerk Collaborate to Advance More Sustainable Printing Ink Solutions with Bio-Based Ethyl Acetate

NexPoint Diversified Real Estate Trust Announces Investor Update Call

JPMorganChase Expands Security and Resiliency Initiative to Canada

Principal Asset Management® Launches Fixed Income ETF Suite